Literature DB >> 1349927

Alterations of the p53 gene in nasopharyngeal carcinoma.

P Effert1, R McCoy, M Abdel-Hamid, K Flynn, Q Zhang, P Busson, T Tursz, E Liu, N Raab-Traub.   

Abstract

Nasopharyngeal carcinoma (NPC) is a malignancy which is consistently associated with the Epstein-Barr virus (EBV). The structure of the EBV genome in NPC suggests that NPC is a clonal proliferation of epithelial cells which emerges after EBV infection. The disease develops with high incidence in specific populations in discrete geographic locations, implicating possible genetic or environmental cofactors. Mutations of the p53 gene are among the most frequent genetic changes found in a large variety of human tumors. Mutations in p53 have been shown to abrogate the suppressor function of wild-type p53 and thus contribute to the transformed phenotype. To determine if mutation in p53 participates in the development of the malignant clone in NPC, the structure and sequence of p53 in 42 primary, metastatic, and nude mouse-passaged NPC specimens was analyzed. A high frequency (6 of 9) of mutations was detected in the nude mouse-passaged tumors, while only 2 of 15 metastatic and 0 of the 18 primary tumors harbored mutant p53. The p53 mutations included single-point mutations and more extensive changes such as frame shifts, deletion, duplication, or complete loss of coding sequences. These data indicate that alterations of the p53 gene are unlikely to be involved in the initial genetic events leading to the clonal outgrowth in NPC. However, although it is a rare NPC which can be established in nude mice, this growth advantage appears to be conferred on tumors bearing a mutant p53.

Entities:  

Mesh:

Year:  1992        PMID: 1349927      PMCID: PMC241162     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Detection of amplified oncogenes by differential polymerase chain reaction.

Authors:  R A Frye; C C Benz; E Liu
Journal:  Oncogene       Date:  1989-09       Impact factor: 9.867

4.  Tumor suppressor genes: the puzzle and the promise.

Authors:  R Sager
Journal:  Science       Date:  1989-12-15       Impact factor: 47.728

5.  Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of beta-interferon gene in chronic myelogenous leukemia.

Authors:  A Neubauer; B Neubauer; E Liu
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

6.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

7.  A variation in the structure of the protein-coding region of the human p53 gene.

Authors:  V L Buchman; P M Chumakov; N N Ninkina; O P Samarina; G P Georgiev
Journal:  Gene       Date:  1988-10-30       Impact factor: 3.688

8.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

9.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma.

Authors:  L S Young; C W Dawson; D Clark; H Rupani; P Busson; T Tursz; A Johnson; A B Rickinson
Journal:  J Gen Virol       Date:  1988-05       Impact factor: 3.891

10.  EBV gene expression in an NPC-related tumour.

Authors:  M M Hitt; M J Allday; T Hara; L Karran; M D Jones; P Busson; T Tursz; I Ernberg; B E Griffin
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

View more
  27 in total

1.  Association of Protein Expression p53 Mutants with Regional Lymph Gland Status on type III Carcinoma Nasofaring Patients.

Authors:  Riza Aswarin; Muhtarum Yusuf; M S Wiyadi
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-05-21

2.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.

Authors:  Laura R Wasil; Leizhen Wei; Christopher Chang; Li Lan; Kathy H Y Shair
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 4.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

5.  Relationship between Epstein-Barr virus-encoded proteins with cell proliferation, apoptosis, and apoptosis-related proteins in gastric carcinoma.

Authors:  Yun Wang; Bing Luo; Li-Ping Yan; Bao-Hua Huang; Peng Zhao
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

6.  Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis.

Authors:  Liangru Ke; Hufeng Zhou; Chong Wang; Geng Xiong; Yanqun Xiang; Yihong Ling; Abdelmajid Khabir; George S Tsao; Yixin Zeng; Musheng Zeng; Pierre Busson; Elliott Kieff; Xiang Guo; Bo Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-22       Impact factor: 11.205

7.  Expression of bcl-2 and p53 proteins in nasopharyngeal carcinoma. Absence of correlation with the presence of EBV encoded EBER1-2 transcripts and latent membrane protein-1.

Authors:  C Kouvidou; P Kanavaros; D Papaioannou; E Stathopoulos; F Sotsiou; G Datseris; M Tzardi; C Kittas; G Delides
Journal:  Clin Mol Pathol       Date:  1995-02

8.  MDM-2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 protein expression.

Authors:  P Kanavaros; C Kouvidou; Y Dai; M Tzardi; G Datseris; K Darivianaki; D Rontogianni; G Delides
Journal:  Clin Mol Pathol       Date:  1995-12

9.  Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.

Authors:  Yock Ping Chow; Lu Ping Tan; San Jiun Chai; Norazlin Abdul Aziz; Siew Woh Choo; Paul Vey Hong Lim; Rajadurai Pathmanathan; Noor Kaslina Mohd Kornain; Chee Lun Lum; Kin Choo Pua; Yoke Yeow Yap; Tee Yong Tan; Soo Hwang Teo; Alan Soo-Beng Khoo; Vyomesh Patel
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

10.  Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas.

Authors:  R H Edwards; N Raab-Traub
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.